KORU Medical Systems, Inc. (KRMD) - 2024 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024. KORU Medical Systems, Inc. develops, manufactures, and commercializes large-volume subcutaneous infusion solutions, primarily the FREEDOM Infusion System, for the delivery of immunoglobulin therapies (treating PIDD and CIDP) and novel drug therapies. The company operates as a single segment with revenues derived from Domestic Core, International Core, and Novel Therapies.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Revenues | $33.6 million | $28.5 million |
| Gross Profit | $21.3 million | $16.7 million |
| Gross Margin | 63.4% | 58.6% |
| Operating Expenses | $27.8 million | $27.0 million |
| Net Loss | $(6.1) million | $(13.7) million |
| Cash and Cash Equivalents | $9.6 million | $11.5 million |
| Inventory | $2.8 million | $3.5 million |
| Debt Obligations | $0.3 million (Insurance financing) | $0.3 million |
Note: The company has a $10 million credit facility ($5M revolving, $5M term) with no outstanding borrowings as of December 31, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 18.0% year-over-year. Growth was driven by a 12.3% increase in Domestic Core, a 31.5% increase in International Core, and a 61.9% surge in Novel Therapies.
- Margin Expansion: Gross margin improved by 480 basis points to 63.4%, attributed to increased manufacturing productivity, improved product mix, and higher average selling prices.
- Loss Reduction: Net loss decreased by 55.9% (from $13.7M to $6.1M). This improvement was primarily due to the significant increase in gross profit, partially offset by a $4.0 million tax benefit reversal in the prior year related to deferred tax assets.
- Operating Expenses: SG&A expenses rose 6.2% due to performance-based bonuses and commissions. R&D expenses decreased 8.4% due to project timing, partially offset by severance costs.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects cash on hand and operating cash flows to meet requirements for at least the next twelve months. Strategic focus remains on expanding the SCIg market, launching a next-generation pump and consumable system, and growing the Novel Therapies segment through biopharmaceutical partnerships.
Key Risks and Contingencies:
- EU MDR Compliance: The company must comply with the EU Medical Device Regulation by December 2028 to continue selling in the EU. Failure to comply will materially impact revenues.
- Supply Chain Concentration: Approximately 85% of consumables are sourced from a single contract manufacturer (Command Medical Products) in Nicaragua. All components are single-sourced.
- Customer Concentration: Six distributors accounted for approximately 75% of net revenues in 2024, with one U.S. distributor contributing 35%.
- Liquidity: While currently adequate, future capital needs for growth may require drawing on the credit facility or raising additional equity/debt.
- Regulatory: Ongoing FDA and international regulatory scrutiny regarding manufacturing, labeling, and off-label promotion.
Investor Verification Checklist
- Verify the timeline and budget for achieving EU MDR compliance by December 2028.
- Assess the stability of the single-source supply chain in Nicaragua and contingency plans for manufacturing interruptions.
- Monitor the concentration risk associated with the top six distributors, particularly the single U.S. distributor representing 35% of revenue.
- Review the progress and revenue recognition of the "Novel Therapies" segment, which grew 61.9% but remains a small portion of total revenue (7.1%).
- Confirm the company's ability to maintain the Adjusted Quick Ratio covenant (minimum 1.50:1.00) required by its credit facility.